Contact Information
37 Westminster Buildings, Theatre Square,
Nottingham, NG1 6LG
Why ChatGPT Is Getting Dumber at Basic Math
Artificial-intelligence chatbots have stoked fears they could spin out of control, but they also suffer from a type of deterioration called ‘drift.’ Source link
AI-Generated Data Could Be a Boon for Healthcare—If Only It Seemed More Real
What to Read Next Source link
Family of Henrietta Lacks, Whose Unique Cells Changed Science, Settles With Thermo Fisher
What to Read Next Source link
Venture Capitalist Seeks to Spur Drug Development for Rare Autoimmune Disease
Venture capitalist Luke Evnin has financed several successful biotechnology startups that develop treatments for cancer. Now he is encouraging drugmakers to tackle another disease: a rare autoimmune condition that
Companies Weigh Growing Power of Cloud Providers Amid AI Boom
A wave of partnerships between AI model makers and cloud providers is leading tech chiefs to assess the benefits of convenience versus becoming too reliant
At the Core of Hollywood's AI Fight: How Far Is Too Far?
Studios see potential in the technology, while actors, writers and other industry workers fear the worst. Source link
Outcry Against AI Companies Grows Over Who Controls Internet’s Content
What to Read Next Source link
The Best-Managed Companies Have the Most AI Jobs Postings. What Explains That?
What to Read Next Source link
As Publishers Seek AI Payments, AP Gets a First-Mover Safeguard
The Associated Press’s pact with OpenAI gives it the right to reset terms if another publisher gets a better deal. Source link
Biogen to Buy Reata in $7.3 Billion Deal
The deal would bolster the biotech company’s portfolio of treatments for neuromuscular and rare diseases. Source link